Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bioprinted-based Tissue Therapy
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $2,675.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $75.0 million
April 12, 2023
Lead Product(s) : Bioprinted-based Tissue Therapy
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $2,675.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
